– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment –
– Data Builds on Previous Evidence on the Association Between Timely Infusion and Patient Outcomes –
– Preliminary Results Supporting Safety and Feasibility of Outpatient